Get AnaptysBio alerts:AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of AnaptysBio in a report released on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will post earnings per share of ($0.85) for the quarter, down from their prior estimate of ($0.84). Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.04 EPS, FY2025 earnings at ($1.69) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($3.01) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at ($0.82) EPS. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Saturday, September 27th. AnaptysBio Company Profile(Get Free Report)AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.